Since being introduced on the market, anti-vascular endothelial growth factor (anti-VEGF) drugs, also known as antiangiogenics, have become widely used as the treatment of choice for retinal diseases such as diabetic macular edema and wet age-related macular degeneration (wet ARMD), both of which are frequent causes of blindness in many populations [1, 2]. The gene discussed is VEGFA; the disease is diabetic macular edema.